Supernus Pharmaceuticals, Inc. (0LB2.L)
USD 31.68
(1.57%)
USD 31.68
(1.57%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | -5.26 Million USD | -80.09% |
| 2022 | 67.3 Million USD | -21.77% |
| 2021 | 86.02 Million USD | -50.47% |
| 2020 | 173.69 Million USD | 16.91% |
| 2019 | 148.57 Million USD | 2.86% |
| 2018 | 144.44 Million USD | 45.11% |
| 2017 | 99.54 Million USD | 83.6% |
| 2016 | 54.21 Million USD | 206.91% |
| 2015 | 17.66 Million USD | -27.09% |
| 2014 | 24.23 Million USD | 139.13% |
| 2013 | -61.92 Million USD | -46.84% |
| 2012 | -42.16 Million USD | -11.7% |
| 2011 | -37.75 Million USD | 5.91% |
| 2010 | -40.12 Million USD | -1099.08% |
| 2009 | 4.01 Million USD | 115.53% |
| 2008 | -25.86 Million USD | -35.77% |
| 2007 | -19.04 Million USD | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q3 | 40.84 Million USD | 124.25% |
| 2024 Q2 | 18.21 Million USD | 528.77% |
| 2024 Q1 | -4.24 Million USD | -122.37% |
| 2023 Q4 | 18.98 Million USD | 133.34% |
| 2023 Q3 | 8.13 Million USD | 146.27% |
| 2023 Q1 | 8.87 Million USD | -74.15% |
| 2023 Q2 | -17.58 Million USD | -298.16% |
| 2023 FY | 13.4 Million USD | -80.09% |
| 2022 FY | 67.3 Million USD | -21.77% |
| 2022 Q4 | 34.33 Million USD | 1844.17% |
| 2022 Q2 | 11.34 Million USD | -34.53% |
| 2022 Q1 | 17.33 Million USD | 184.19% |
| 2022 Q3 | 1.76 Million USD | -84.44% |
| 2021 Q3 | 32.6 Million USD | -4.42% |
| 2021 Q1 | 13.21 Million USD | -69.27% |
| 2021 FY | 86.02 Million USD | -50.47% |
| 2021 Q2 | 34.11 Million USD | 158.16% |
| 2021 Q4 | 6.09 Million USD | -81.3% |
| 2020 Q3 | 56.14 Million USD | 23.25% |
| 2020 Q2 | 45.54 Million USD | 57.0% |
| 2020 Q1 | 29.01 Million USD | -28.92% |
| 2020 FY | 173.69 Million USD | 16.91% |
| 2020 Q4 | 42.99 Million USD | -23.41% |
| 2019 Q1 | 25.42 Million USD | -36.2% |
| 2019 Q3 | 39.72 Million USD | -6.74% |
| 2019 Q2 | 42.59 Million USD | 67.52% |
| 2019 Q4 | 40.81 Million USD | 2.74% |
| 2019 FY | 148.57 Million USD | 2.86% |
| 2018 FY | 144.44 Million USD | 45.11% |
| 2018 Q1 | 31.39 Million USD | -8.59% |
| 2018 Q2 | 35.72 Million USD | 13.78% |
| 2018 Q3 | 37.47 Million USD | 4.91% |
| 2018 Q4 | 39.85 Million USD | 6.35% |
| 2017 Q1 | 16.78 Million USD | 3.02% |
| 2017 Q3 | 22.34 Million USD | -14.29% |
| 2017 Q4 | 34.34 Million USD | 53.72% |
| 2017 FY | 99.54 Million USD | 83.6% |
| 2017 Q2 | 26.06 Million USD | 55.27% |
| 2016 Q3 | 19.83 Million USD | 90.03% |
| 2016 Q2 | 10.44 Million USD | 96.31% |
| 2016 Q1 | 5.31 Million USD | -22.35% |
| 2016 FY | 54.21 Million USD | 206.91% |
| 2016 Q4 | 16.29 Million USD | -17.86% |
| 2015 Q2 | 3.07 Million USD | -10.32% |
| 2015 Q3 | 4.3 Million USD | 40.08% |
| 2015 Q4 | 6.84 Million USD | 58.95% |
| 2015 FY | 17.66 Million USD | -27.09% |
| 2015 Q1 | 3.43 Million USD | -27.47% |
| 2014 Q4 | 4.72 Million USD | -83.79% |
| 2014 Q3 | 29.16 Million USD | 676.54% |
| 2014 Q2 | 3.75 Million USD | 127.98% |
| 2014 FY | 24.23 Million USD | 139.13% |
| 2014 Q1 | -13.42 Million USD | -18.18% |
| 2013 Q1 | -17.9 Million USD | -40.52% |
| 2013 Q3 | -17.17 Million USD | -10.96% |
| 2013 Q4 | -11.35 Million USD | 33.87% |
| 2013 FY | -61.92 Million USD | -46.84% |
| 2013 Q2 | -15.47 Million USD | 13.56% |
| 2012 Q2 | -9.25 Million USD | -17.5% |
| 2012 Q4 | -12.74 Million USD | -3.69% |
| 2012 FY | -42.16 Million USD | -11.7% |
| 2012 Q3 | -12.29 Million USD | -32.76% |
| 2012 Q1 | -7.87 Million USD | 60.86% |
| 2011 Q3 | -9.91 Million USD | -18.09% |
| 2011 Q4 | -20.13 Million USD | -103.03% |
| 2011 FY | -37.75 Million USD | 5.91% |
| 2011 Q2 | -8.39 Million USD | 8.72% |
| 2011 Q1 | -9.19 Million USD | 52.55% |
| 2010 FY | -40.12 Million USD | -1099.08% |
| 2010 Q4 | -19.38 Million USD | 0.0% |
| 2009 FY | 4.01 Million USD | 115.53% |
| 2009 Q4 | -13.74 Million USD | 0.0% |
| 2008 FY | -25.86 Million USD | -35.77% |
| 2007 FY | -19.04 Million USD | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| Thermo Fisher Scientific Inc. | 6.85 Billion USD | 100.077% |
| Dynavax Technologies Corporation | -37.02 Million USD | 85.77% |
| Illumina, Inc. | -1.06 Billion USD | 99.507% |
| IQVIA Holdings Inc. | 1.97 Billion USD | 100.267% |
| Biogen Inc. | 1.29 Billion USD | 100.406% |
| Iovance Biotherapeutics, Inc. | -460.55 Million USD | 98.856% |
| Mettler-Toledo International Inc. | 1.08 Billion USD | 100.485% |
| Sarepta Therapeutics, Inc. | -267.82 Million USD | 98.033% |
| Waters Corporation | 817.67 Million USD | 100.644% |
| Perrigo Company plc | 151.9 Million USD | 103.469% |
| uniQure N.V. | -282.87 Million USD | 98.137% |
| Agios Pharmaceuticals, Inc. | -391.48 Million USD | 98.654% |
| Amicus Therapeutics, Inc. | -73.49 Million USD | 92.831% |
| Atara Biotherapeutics, Inc. | -276 Million USD | 98.091% |
| bluebird bio, Inc. | -244.26 Million USD | 97.843% |
| Cara Therapeutics, Inc. | -121.49 Million USD | 95.663% |
| Imunon, Inc. | -21.03 Million USD | 74.946% |
| Myriad Genetics, Inc. | -123.7 Million USD | 95.741% |
| Neurocrine Biosciences, Inc. | 250.9 Million USD | 102.1% |
| Nektar Therapeutics | -137.42 Million USD | 96.166% |
| Editas Medicine, Inc. | -169.18 Million USD | 96.886% |
| Verastem, Inc. | -92.08 Million USD | 94.278% |
| Walgreens Boots Alliance, Inc. | -14.07 Billion USD | 99.963% |
| Corbus Pharmaceuticals Holdings, Inc. | -45.07 Million USD | 88.311% |
| Heron Therapeutics, Inc. | -110.61 Million USD | 95.237% |
| Unity Biotechnology, Inc. | -44.66 Million USD | 88.204% |
| BioMarin Pharmaceutical Inc. | 194.44 Million USD | 102.71% |
| Sangamo Therapeutics, Inc. | -274 Million USD | 98.077% |
| Evolus, Inc. | -49.23 Million USD | 89.298% |
| Adicet Bio, Inc. | -152.03 Million USD | 96.534% |
| Aclaris Therapeutics, Inc. | -97.35 Million USD | 94.588% |
| Regeneron Pharmaceuticals, Inc. | 4.04 Billion USD | 100.13% |
| Esperion Therapeutics, Inc. | -155.56 Million USD | 96.613% |
| FibroGen, Inc. | -281.81 Million USD | 98.13% |
| Agilent Technologies, Inc. | 1.35 Billion USD | 100.39% |
| OPKO Health, Inc. | -157.02 Million USD | 96.644% |
| Homology Medicines, Inc. | -48.25 Million USD | 89.081% |
| Geron Corporation | -193.94 Million USD | 97.283% |
| Alnylam Pharmaceuticals, Inc. | -282.17 Million USD | 98.133% |
| Exelixis, Inc. | 170.88 Million USD | 103.083% |
| Viking Therapeutics, Inc. | -100.82 Million USD | 94.774% |
| Anavex Life Sciences Corp. | -55.75 Million USD | 90.55% |
| Intellia Therapeutics, Inc. | -515.29 Million USD | 98.977% |
| Zoetis Inc. | 3.06 Billion USD | 100.172% |
| Axsome Therapeutics, Inc. | -231.82 Million USD | 97.727% |
| Abeona Therapeutics Inc. | -48.2 Million USD | 89.068% |
| Vertex Pharmaceuticals Incorporated | 4.3 Billion USD | 100.122% |
| Kala Pharmaceuticals, Inc. | -39.15 Million USD | 86.543% |
| Ionis Pharmaceuticals, Inc. | -353.73 Million USD | 98.51% |
| Corcept Therapeutics Incorporated | 107.28 Million USD | 104.911% |
| Halozyme Therapeutics, Inc. | 337.57 Million USD | 101.561% |
| Blueprint Medicines Corporation | -486.27 Million USD | 98.916% |
| Insmed Incorporated | -709.62 Million USD | 99.257% |
| TG Therapeutics, Inc. | 20.63 Million USD | 125.537% |
| Incyte Corporation | 620.52 Million USD | 100.849% |
| Emergent BioSolutions Inc. | -726.4 Million USD | 99.275% |